KUALA LUMPUR: Kenanga Research has maintained its "underperform" recommendation on Pharmaniaga Bhd following the release of underwhelming earnings results.
The research house said the group's 9MFY20 core PATAMI was below its expectation at 50% and 47% of its and consensus' full-year estimates.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!